Scholars Central

Review articlePublished 2018

Prognosis of Patients with Neuroendocrine Neoplasms of the Pancreas According to the World Health Organization 2017 Classification

Authors: Yuki Ueda, Hirochika Toyama, Takumi Fukumoto, Yonson Ku

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pancreatic neuroendocrine neoplasms are rare tumors with diverse biological behavior. World Health Organization classifications 2010 of neuroendocrine neoplasms based on Ki67 and Mitotic indexes has been widely accepted as correlating favorably with patient prognosis. WHO classification 2017 has been updated on the basis of recent studies on pathological differentiation of “G3 tumors” in the 2010 classification. Neuroendocrine neoplasms are largely classified into well differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas based on their pathological differentiation. NETs are further classified into NET G1, G2, and G3 based on their Ki67 and Mitotic indexes; NECs are classified as NEC G3. In this review, WHO classification, TNM classification and further prognostic factors are described.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Yuki Ueda”
  • BylineArticles whose byline prints “Hirochika Toyama”
  • BylineArticles whose byline prints “Takumi Fukumoto”
  • BylineArticles whose byline prints “Yonson Ku”